Navigation Links
Genesis Biopharma Conference Call and Webcast Reminder

LOS ANGELES, June 28, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, is holding a conference call with the investment community tomorrow, Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).  The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.  There will also be a question and answer session following the presentation.

Individuals interested in listening to the conference call may do so by dialing 888-634-9408 for domestic callers, or 706-679-0879 for international callers, or from the webcast on the investor relations section of the Company's Web site at  A slide presentation will accompany the call and webcast, and will be available on the Company website.

A telephone replay will be available through July 1, 2011 by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering the Conference ID #: 78126182.  The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
2. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
3. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
4. ThermoGenesis Announces China Customer Implements Cord Blood Products
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
7. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
8. Announcing ValGenesis On-Demand SaaS Solution
9. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
10. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
11. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the ... network, a depiction of a system of linkages and connections so complex and ... professor of computer science at Worcester Polytechnic Institute (WPI) and director of the ...
(Date:10/12/2017)... JOHNSTON, Iowa (PRWEB) , ... October 12, 2017 ... ... company based in Vilnius, Lithuania, announced today that they have entered into a ... collaboration is to provide CRISPR researchers with additional tools for gene editing across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):